Global X Lithium & Battery Tech ETF vs Nuwellis Inc — how do they compare? Global X Lithium & Battery Tech ETF trades at $69.73 (market cap $1.45B), while Nuwellis Inc trades at $0.69 (market cap $2.20M). The key difference: Global X Lithium & Battery Tech ETF is far larger — about 659.1× Nuwellis Inc's market cap, and Global X Lithium & Battery Tech ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Lithium & Battery Tech ETF for 56 Days and Nuwellis Inc for 26 Days on average.
| LIT | NUWE | |
|---|---|---|
Market Cap | $1.45B | $2.20M |
Volume | 89,392 | 121,544 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $91.62 | $146.65 |
52-Week Low | $53.92 | $0.68 |
Typical Hold Time | 56 Days | 26 Days |
Enterprise Value | — | -$1.52M |
Signals from Pluang's Aura AI — not financial advice
LIT trades at $69.73, up 0.32% with mixed technical signals showing a bullish overall trend but bearish moving averages and oscillators. The ETF's price action remains volatile, trading near key support/resistance levels. Recent news highlights significant short interest reduction and ongoing exposure to the lithium and battery technology sector, which faces both supply chain challenges and long-term growth potential from electric vehicle adoption.
The outlook for LIT is cautiously optimistic, driven by global EV adoption trends and energy storage demand, though tempered by lithium price volatility and competitive pressures. Key risks include commodity price swings and geopolitical factors affecting battery supply chains, while institutional sentiment shows mixed signals with technical indicators suggesting near-term consolidation.
NUWE trades at $0.689, down 0.25% with a bearish technical signal despite oversold RSI readings. The company shows promising revenue growth (14% YoY in Q2 2026) and strong gross margins (69.69%), but faces significant profitability challenges with a -125.63% net income margin and negative cash flow. Recent news highlights console adoption growth and strategic expansions in pediatric care.
While NUWE's valuation metrics appear attractive (P/E 0.03, P/S 0.01), the company's persistent losses and negative cash flow present substantial risk. Analyst sentiment is mixed with a 50/50 buy/hold split. The stock offers speculative potential if management can achieve profitability, but requires careful risk assessment given current financial challenges.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →